Patents Assigned to Nkarta, Inc.
  • Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
    Patent number: 11365236
    Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: June 21, 2022
    Assignees: NKARTA, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
  • CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
    Patent number: 11253547
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 22, 2022
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • Cancer immunotherapy using CD19-directed chimeric antigen receptors
    Patent number: 11154575
    Abstract: Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: October 26, 2021
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
  • Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
    Patent number: 11141436
    Abstract: Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: October 12, 2021
    Assignee: Nkarta, Inc.
    Inventors: James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic